European Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods by Compulsory Contributory Health Insurance Schemes and Compulsory Medical Saving Accounts (CMSA) by Country

In 2024, Germany leads with €51.05 billion spent on pharmaceuticals and medical non-durable goods via compulsory health insurance and saving schemes, followed by France with €32.86 billion. Switzerland and the Netherlands, at €5.28 billion and €4.12 billion, respectively, complete the top four. Notable year-on-year growth was observed in countries like Lithuania (15.04%) and Bosnia and Herzegovina (7.13%). Greece and Portugal experienced a decline, with Greece at -5.25% and Portugal at -27.3%. The 5-year CAGR indicates stable growth across most countries.

Future trends to watch include the potential impacts of healthcare policy changes in the EU, advancements in pharmaceutical technology, and demographic shifts influencing demand. Additionally, economic fluctuations and geopolitical dynamics might affect funding and expenditure priorities, possibly leading to more varied investment across Europe in pharmaceuticals and medical goods.